Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이지환 | - |
dc.date.accessioned | 2019-10-29T16:30:34Z | - |
dc.date.available | 2019-10-29T16:30:34Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1539-2864 | - |
dc.identifier.other | OAK-25514 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251678 | - |
dc.description.abstract | PURPOSE: To evaluate the efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration unresponsive to anti-vascular endothelial growth factor therapy. METHODS: This retrospective, interventional study included 15 patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor. Patients used topical dorzolamide-timolol twice daily in the neovascular age-related macular degeneration eye and received anti-vascular endothelial growth factor therapy at each visit, with the same fixed interval and agent as before the addition of dorzolamide-timolol. Central macular thickness, maximal subretinal fluid height, and maximal pigment epithelial detachment height were measured at baseline and every visit. RESULTS: The mean follow-up period was 17.2 ± 5.5 weeks. The mean central macular thickness decreased from 383.5 μm at baseline to 298.3 μm at the final visit (P = 0.041). The mean maximal subretinal fluid height decreased from 105.0 μm at baseline to 58.3 μm at the final visit (P = 0.021). Complete resolution of subretinal fluid was observed in 3 of 11 subretinal fluid-type eyes. There was no significant change in the maximal pigment epithelial detachment height. The mean logarithm of the minimum angle of resolution visual acuity decreased from 0.61 (20/81 Snellen) at baseline to 0.66 (20/91 Snellen) at final visit, which was not significant (P = 0.314). The mean intraocular pressure decreased significantly from 14.9 mmHg at baseline to 12.3 mmHg at the final visit (P = 0.005). CONCLUSION: The use of adjuvant topical dorzolamide-timolol was effective in decreasing central macular thickness and subretinal fluid in patients with neovascular age-related macular degeneration refractory to continual fixed-interval intravitreal anti-vascular endothelial growth factor therapy, but did not result in functional improvement in this short-term study. | - |
dc.language | English | - |
dc.publisher | NLM (Medline) | - |
dc.title | EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY | - |
dc.type | Article | - |
dc.relation.issue | 10 | - |
dc.relation.volume | 39 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 1953 | - |
dc.relation.lastpage | 1958 | - |
dc.relation.journaltitle | Retina (Philadelphia, Pa.) | - |
dc.identifier.doi | 10.1097/IAE.0000000000002293 | - |
dc.identifier.scopusid | 2-s2.0-85072785732 | - |
dc.author.google | Lee J.H. | - |
dc.author.google | Lee S.C. | - |
dc.author.google | Byeon S.H. | - |
dc.author.google | Koh H.J. | - |
dc.author.google | Kim S.S. | - |
dc.author.google | Lee C.S. | - |
dc.contributor.scopusid | 이지환(56579746800) | - |
dc.date.modifydate | 20220428134029 | - |